Francesco S.
- Country
- Belgium
- Department
- Gastroenterology
Research Overview
- Sotorasib and Combination Therapy Versus Standard Chemotherapy in Treatment-Naïve Patients with KRAS p.G12C-Mutated Metastatic Colorectal Cancer
- Randomized Phase 3 Trial of Telisotuzumab adizutecan plus bevacizumab versus trifluridine/tipiracil plus bevacizumab in refractory metastatic colorectal cancer
- Evaluation of Amivantamab Monotherapy and Combination with Standard Chemotherapy in Advanced or Metastatic Colorectal Cancer
Data & Insights
Has run more than one trial at 161 of 337 partner sites.
Specializations
Colorectal Cancer Specialization
The investigator focuses on treating various forms of advanced and metastatic colorectal cancer, with particular emphasis on cases involving specific genetic mutations and biomarkers.
- KRAS/NRAS and BRAF wild-type colorectal cancer
- HER2-positive metastatic colorectal cancer
- MSI-H/dMMR colorectal cancer variants
Their research extends to both left-sided and general metastatic colorectal cancer presentations.
Treatment Approaches
The investigator specializes in evaluating innovative therapeutic combinations including immunotherapy and targeted treatments.
- Combined immunotherapy regimens
- Targeted molecular therapies
- Neoadjuvant treatment strategies
Their work encompasses both early-stage and advanced disease management protocols.
Gastrointestinal Oncology
The investigator's expertise extends to treating gastric and gastroesophageal junction adenocarcinoma, investigating both standard and novel therapeutic approaches.
- Locally advanced resectable gastric cancer
- Perioperative treatment protocols
- Combination therapy strategies
Their research includes evaluation of various chemotherapy combinations and targeted treatments.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.